Here, we report an additional case: a 69-year-old female, who originally presented with axonal sensory and motor neuropathy at the age of 45, associated with moderate sensorineural hearing loss, with a slight slope at high frequencies. Next-generation sequencing identified a novel path-
(CMTDIG) has been confirmed. [2] [3] [4] Pathogenic variants in the NEFL gene have been observed in less than 1% of CMT cases, 5 resulting in the reporting of 35 in 173 CMT patients to date. However, only six variants have been reported in 17 patients with impaired hearing. 5 No genotype-phenotype correlations have been yet established.
Here, we report the case of a 69-year-old female who presented CMT and deafness associated with a new variant. We sought phenotype-genotype correlations of these specific features through a review of the literature.
| MATERIALS AND METHODS

Patient:
The patient was a 69-year-old female who originally presented features of CMT at the age of 45 years. Peripheral blood was collected in ethylenediamine tetraacetic acid (EDTA) tubes after she provided her informed consent. The protocol was in accordance with French ethics legislation.
Pathogenic variant detection: Genomic DNA was extracted using standard methods (Illustra DNA Extraction kit BACC3, GEHC). Nextgeneration sequencing (NGS) was performed using a custom 92-gene panel designed for the diagnosis of CMT and associated neuropathies ( 3 | RESULTS
| Clinical description
The patient was a 69-year-old female who had suffered from sensory and motor neuropathy since the age of 45. Her symptoms were more 
| Genetic testing
We performed NGS using a large custom panel of CMT genes and The mother could not be tested, as she was dead.
| Two-dimensional protein model
The pathogenic variant observed in our patient, is located just after the filament head domain. The new variant and the six already published for neuropathy associated with deafness are presented in a two-dimensional-model ( Figure 3 ). All are located at the end of a specific domain, except for the deletion.
Establishing genotype-phenotype correlations in patients with NEFL-based neuropathies associated with deafness is difficult as the prevalence and number of variants are low.
| DISCUSSION
We report the case of a 69-year-old female who originally developed axonal sensory-motor polyneuropathy associated with moderate deafness at high frequencies at the age of 45. NGS showed this patient to have a new missense variant of NEFL, located at the head of the protein.
In our cohort of 3412 CMT patients, a second female patient, aged 10 years, had a pathogenic variant of NEFL, c.293A > G, p.
(Asn98Ser), already reported with the same phenotype. 6 She had suf- (Table 1) . Familial and sporadic cases were equivalent. In familial cases, hearing loss was not always associated with neuropathy within the same family. However, additional studies, such as an audiogram or auditory brainstem response (ABR), were not performed on these families. Molecular strategies to study these patients consisted of Sanger sequencing of the NEFL gene. We localised these patho- 10 The reported audiological curves correspond to ours and could therefore be considered to be a phenotype-genotype correlation ( Figure 1) . We suggest that a complete audiometry test should be performed in patients who present CMT associated with these variants, as deafness may be underestimated. We used MLPA and Sanger sequencing for GJB2 and GJB6 to screen for hearing loss in our study. This is the first time this strategy has been reported, as hearing loss could also be due to the involvement of another gene. Sural nerve biopsies have shown onion bulbs, as well as several axonal regeneration clusters, sometimes associated with an onion bulb. They also showed a paucity of large myelinated fibres and a few large fibres had thin myelin sheaths. Irregular folding of myelin sheaths were also observed, 2 In cases of chronic axonal neuropathy, focal accumulations of NF with axonal swellings, such as giant axons, and significant secondary demyelination were observed. 8 In case of the p.(Glu396Lys) pathogenic variant, a decrease in neurofilament abundance has been described as a pathological marker. The lack of NF aggregates suggests that they occur proximally, leading to subsequent alterations in the axonal cytoskeleton. The small axonal calibre, along with the normal molecular architecture of nodes and paranodes, explain the reduced velocities detected in some patients. 12 Transient transfection studies have also suggested that p.(Glu90Gly) and p.
(Asn98Ser) result in NFL assembly defects. 13 The p.(Asn98Ser) and p.
(Glu396Lys) pathogenic variants resulted in cytoplasmic protein aggregates. These aggregates appear to prevent the transport of NEFL to axons. Depletion of neurofilaments in axons would result in small axon calibre and thus a slower conduction velocity. 14 This is in accordance with the study of the functional protein just described. However, nothing has been described in the cochlea. Indeed, there is very little information concerning hearing impairment. Thus, we cannot determine whether deafness is due to a cochlear defect or alteration of the auditory nerves. For example, our patient presented sensorineural neuropathy without any sign of auditory neuropathy. . 16 Pathogenic variants of NEFL responsible for CMT are rare and associated with various phenotypes. However, deafness is often linked to neuropathy, especially for pathogenic variants p.(Glu90Lys) and p.
(Asn98Ser) and our p.(Glu90Gly) pathogenic variant. These pathogenic variants are all located at hot spots: in the head domain and the two ends of the rod domain. Deafness is probably underdiagnosed and should be better reported to improve our understanding of the physiopathology common to these two conditions. Thus, in cases of neuropathy associated with deafness, sequencing of NEFL should be considered and, conversely, testing for hearing impairment should be performed on neuropathic patients harbouring pathogenic NEFL variants.
